RU2017126044A - Соединение тиотриазола и его применения при лечении паразитарных протозойных инфекций - Google Patents
Соединение тиотриазола и его применения при лечении паразитарных протозойных инфекций Download PDFInfo
- Publication number
- RU2017126044A RU2017126044A RU2017126044A RU2017126044A RU2017126044A RU 2017126044 A RU2017126044 A RU 2017126044A RU 2017126044 A RU2017126044 A RU 2017126044A RU 2017126044 A RU2017126044 A RU 2017126044A RU 2017126044 A RU2017126044 A RU 2017126044A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- indol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 20
- 208000015181 infectious disease Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 11
- 230000003071 parasitic effect Effects 0.000 claims 5
- 208000028172 protozoa infectious disease Diseases 0.000 claims 4
- JYZATACFRNCXLC-DMPGVRBJSA-N (2R)-2-[[3-(3,5-dichloropyridin-4-yl)-1,2-dihydro-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)propan-1-one Chemical compound ClC=1C=NC=C(C=1C1(NNC=N1)S[C@@H](C(=O)C1=CNC2=CC=CC=C12)C)Cl JYZATACFRNCXLC-DMPGVRBJSA-N 0.000 claims 2
- BAABPIIOLPSIKR-SECBINFHSA-N (2R)-2-[[5-(3,5-dichloropyridin-4-yl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)propan-1-one Chemical compound ClC=1C=NC=C(C=1C1=NNC(=N1)S[C@@H](C(=O)C1=CNC2=CC=CC=C12)C)Cl BAABPIIOLPSIKR-SECBINFHSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- BAABPIIOLPSIKR-VIFPVBQESA-N (2S)-2-[[5-(3,5-dichloropyridin-4-yl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)propan-1-one Chemical compound ClC=1C=NC=C(C=1C1=NNC(=N1)S[C@H](C(=O)C1=CNC2=CC=CC=C12)C)Cl BAABPIIOLPSIKR-VIFPVBQESA-N 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 206010037075 Protozoal infections Diseases 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (18)
1. Соединение формулы (I):
(R)-2-((3-(3,5-дихлорпиридин-4-ил)-1H-1,2,4-триазол-5-ил)тио)-1-(1H-индол-3-ил)пропан-1-он
или его таутомерная форма.
2. Таутомерная форма соединения формулы (I) по п.1, представляющая собой:
(R)-2-((3-(3,5-дихлорпиридин-4-ил)-1H-1,2,4-триазол-3-ил)тио)-1-(1H-индол-3-ил)пропан-1-он.
3. Фармацевтически приемлемая соль соединения формулы (I) по п.1 или 2.
4. Фармацевтическая композиция, содержащая (a) соединение формулы (I) по п.1 или 2, или его фармацевтически приемлемую соль, и (b) один или более фармацевтически приемлемых носителей.
5. Соединения формулы (I) по п.1 или 2, или его фармацевтически приемлемая соль, для применения в терапии.
6. Соединения формулы (I) по п.1 или 2, или его фармацевтически приемлемая соль, для применения для лечения паразитарной протозойной инфекции.
7. Применение соединения формулы (I) по п.1 или 2, или его фармацевтически приемлемой соли для получения лекарственного средства для лечения паразитарной протозойной инфекции.
8. Комбинация (a) соединения формулы (I) по п.1 или 2, или его фармацевтически приемлемой соли, и (b) по меньшей мере одного противомалярийного средства.
9. Способ лечения субъекта, являющегося человеком или животным, страдающего паразитарной протозойной инфекцией, включающий введение указанному субъекту, являющемуся человеком или животным, эффективного количества соединения формулы (I) по п.1 или 2, или его фармацевтически приемлемой соли.
10. Соединение для применения по п.5, соединение для применения по п.6, соединение для применения в комбинации для применения по п.7, или соединение для применения по п.8, где паразитарная протозойная инфекция представляет собой малярию.
11. Соединение для применения по п.5, соединение для применения по п.6, соединение для применения в комбинации для применения по п.7, или соединение для применения по п.8, где паразитарная протозойная инфекция представляет собой Plasmodium falciparum.
12. Смесь, содержащая соединение формулы (I), (R)-2-((3-(3,5-дихлорпиридин-4-ил)-1H-1,2,4-триазол-5-ил)тио)-1-(1H-индол-3-ил)пропан-1-он по п.1 или его соль и его энантиомер (S)-2-((3-(3,5-дихлорпиридин-4-ил)-1H-1,2,4-триазол-5-ил)тио)-1-(1H-индол-3-ил)пропан-1-он или его соль.
13. Смесь, содержащая соединение формулы (IА), (R)-2-((3-(3,5-дихлорпиридин-4-ил)-1H-1,2,4-триазол-3-ил)тио)-1-(1H-индол-3-ил)пропан-1-он, по п.2 или его соль и его энантиомер (S)-2-((3-(3,5-дихлорпридин-4-ил)-1H-1,2,4-триазол-3-ил)тио)-1-(1H-индол-3-ил)пропан-1-он или его соль.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382555.2 | 2014-12-22 | ||
| EP14382555 | 2014-12-22 | ||
| PCT/EP2015/080730 WO2016102431A1 (en) | 2014-12-22 | 2015-12-21 | Thiotriazole compound and its use in parasitic protozoal infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017126044A true RU2017126044A (ru) | 2019-01-24 |
Family
ID=52146396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017126044A RU2017126044A (ru) | 2014-12-22 | 2015-12-21 | Соединение тиотриазола и его применения при лечении паразитарных протозойных инфекций |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170368034A1 (ru) |
| EP (1) | EP3237400A1 (ru) |
| JP (1) | JP2017538776A (ru) |
| KR (1) | KR20170097051A (ru) |
| CN (1) | CN107108572A (ru) |
| AR (1) | AR103219A1 (ru) |
| AU (1) | AU2015371169A1 (ru) |
| BR (1) | BR112017013545A2 (ru) |
| CA (1) | CA2971668A1 (ru) |
| PE (1) | PE20171081A1 (ru) |
| PH (1) | PH12017501072A1 (ru) |
| RU (1) | RU2017126044A (ru) |
| SG (1) | SG11201704584RA (ru) |
| TW (1) | TW201636340A (ru) |
| UY (1) | UY36469A (ru) |
| WO (1) | WO2016102431A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210022646A (ko) * | 2018-06-19 | 2021-03-03 | 노파르티스 아게 | 시아노트리아졸 화합물 및 이의 용도 |
| AU2020405068A1 (en) * | 2019-12-18 | 2022-07-07 | Stinginn Llc | Substituted 1,2, 4-triazoles and methods of use |
-
2015
- 2015-12-21 AU AU2015371169A patent/AU2015371169A1/en not_active Abandoned
- 2015-12-21 EP EP15817827.7A patent/EP3237400A1/en not_active Withdrawn
- 2015-12-21 BR BR112017013545A patent/BR112017013545A2/pt not_active Application Discontinuation
- 2015-12-21 PE PE2017000989A patent/PE20171081A1/es not_active Application Discontinuation
- 2015-12-21 RU RU2017126044A patent/RU2017126044A/ru unknown
- 2015-12-21 KR KR1020177017016A patent/KR20170097051A/ko unknown
- 2015-12-21 US US15/537,637 patent/US20170368034A1/en not_active Abandoned
- 2015-12-21 WO PCT/EP2015/080730 patent/WO2016102431A1/en active Application Filing
- 2015-12-21 CA CA2971668A patent/CA2971668A1/en not_active Abandoned
- 2015-12-21 SG SG11201704584RA patent/SG11201704584RA/en unknown
- 2015-12-21 JP JP2017533570A patent/JP2017538776A/ja active Pending
- 2015-12-21 AR ARP150104227A patent/AR103219A1/es unknown
- 2015-12-21 CN CN201580070247.3A patent/CN107108572A/zh active Pending
- 2015-12-21 TW TW104142896A patent/TW201636340A/zh unknown
- 2015-12-21 UY UY0001036469A patent/UY36469A/es unknown
-
2017
- 2017-06-08 PH PH12017501072A patent/PH12017501072A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017538776A (ja) | 2017-12-28 |
| PE20171081A1 (es) | 2017-08-03 |
| PH12017501072A1 (en) | 2017-11-27 |
| AU2015371169A1 (en) | 2017-06-29 |
| SG11201704584RA (en) | 2017-07-28 |
| AR103219A1 (es) | 2017-04-26 |
| WO2016102431A1 (en) | 2016-06-30 |
| UY36469A (es) | 2016-06-30 |
| BR112017013545A2 (pt) | 2018-03-06 |
| US20170368034A1 (en) | 2017-12-28 |
| CN107108572A (zh) | 2017-08-29 |
| CA2971668A1 (en) | 2016-06-30 |
| TW201636340A (zh) | 2016-10-16 |
| KR20170097051A (ko) | 2017-08-25 |
| EP3237400A1 (en) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| JP2016536286A5 (ru) | ||
| JP2016034978A5 (ru) | ||
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2015522018A5 (ru) | ||
| JP2017517512A5 (ru) | ||
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
| JP2015521156A5 (ru) | ||
| JP2016510326A5 (ru) | ||
| JP2016537338A5 (ru) | ||
| PH12015501945A1 (en) | Formulations of organic compounds | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| RU2017126044A (ru) | Соединение тиотриазола и его применения при лечении паразитарных протозойных инфекций | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| RU2017134285A (ru) | Борсодержащие низкомолекулярные соединения как антипротозойные агенты | |
| EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| WO2012163088A3 (zh) | 肾病和心脏病的治疗药物及其用途 | |
| JP2014509637A5 (ru) | ||
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| JP2020530023A5 (ru) | ||
| RU2015131803A (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |